Frencken’s diversified revenue from medical and semiconductor sectors provides ‘resilience’: DBS

SINGAPORE (July 1): Amid the novel coronavirus (Covid-19) pandemic and expectations of higher global fabrication equipment spending, Frencken Group’s diversified revenue streams should bode well for the company, according to DBS Group Research.

This should provide “resilience” and “stability” to the equipment service provider, the brokerage adds.

According to DBS, about 19% of the company’s revenue is derived from the medical segment, which is an added advantage during the pandemic.

---

Related Stories

• Right after Valuetronics, fund manager Amova emerges as a substantial shareholder of Frencken Group
• RHB's Yeo raises target price for Frencken from $2.03 to $2.56
• Frencken’s 2H comes in line but poised for pick-up in semiconductor-related demand

---